Our results indicate that the MR1-restricted cancer-activated T cells we describe may also reside in this CD161+CD8+ T cell population and might be specifically demarked from the majority of CD161+CD8+ T cells by their lack of TRAV1-2 and CD8-αα expression (TRAV1-2neg, CD8αβ+, CD161lo/med), although further work will be required to confirm this. This evidence concerns the gene TRAV1-2 and cancer.